Transcode Therapeutics RNAZ
NASDAQ RNAZ
$1.70 -0.08 (-4.49%)
As of: Sep 10, 2026 · 3:58 PM EDT

Transcode Therapeutics (RNAZ) Current Leases (2023 - 2024)

Transcode Therapeutics' (RNAZ) quarterly Current Leases came in at $38291.0 in Q4 2024, down 90.71% on a YoY basis from $412280.0 in Q1 2024, and down 74.89% quarter-over-quarter from $152481.0 in Q3 2024.

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo
Analysis

Transcode Therapeutics (RNAZ) Current Leases (2023 - 2024) Analysis & Trends

Transcode Therapeutics (RNAZ) has reported Current Leases for 2 consecutive years, with $38291.0 the latest figure, recorded in Q4 2024.

  • For the quarter ending Q4 2024, Current Leases fell 90.71% year-over-year to $38291.0; the trailing twelve-month figure through Dec 2024 stood at $38291.0 (down 90.71% YoY), and the FY2024 full-year result was $38291.0, down 90.71% from the prior year.
  • Current Leases retreated to $38291.0 in Q4 2024 per RNAZ's latest filing, from $152481.0 in the prior quarter.
  • Across five years, Current Leases topped out at $412280.0 in Q4 2023 and bottomed at $38291.0 in Q4 2024.
Peer Set

Peer Comparison

All peers
# Company Market Cap Enterprise Value Gross Profit (Qtr) Current Leases (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn -
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn -
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 720.00 Mn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn 11.00 Mn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn 45.93 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn -
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn 12.38 Mn
10 Transcode Therapeutics 1.63 Mn 1.63 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 38,291.00
Sep 30, 2024 152,481.00
Jun 30, 2024 227,246.00
Mar 31, 2024 339,408.00
Dec 31, 2023 412,280.00
Sep 30, 2023 404,928.00
Jun 30, 2023 397,641.00
Mar 31, 2023 390,419.00